![EPO Board of Appeal finds Broad Institute’s CRISPR patent to lack valid priority claim and upholds revocation of patent (T 0844/18) EPO Board of Appeal finds Broad Institute’s CRISPR patent to lack valid priority claim and upholds revocation of patent (T 0844/18)](/media/1871/judge-1587300_640.jpg?anchor=center&mode=crop&width=385&height=215&rnd=133651879990000000)
EPO Board of Appeal finds Broad Institute’s CRISPR patent to lack valid priority claim and upholds revocation of patent (T 0844/18)
This week’s hearing at the EPO concerning Broad Institute’s CRISPR/Cas9 patent was arguably one of the most high-profile appeals recently...